Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$5.60

0.05 (0.90%)

, MRK

Merck

$63.89

0.89 (1.41%)

06:03
05/19/17
05/19
06:03
05/19/17
06:03

Dynavax to present data on SD-101 in combination with KEYTRUDA at ASCO

Dynavax (DVAX) announced that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA, an anti-PD-1 therapy developed by Merck (MRK), will be presented in a poster at the 2017 American Society of Clinical Oncology Annual Meeting. The poster presentation will include updated data from those in the abstract.

DVAX

Dynavax

$5.60

0.05 (0.90%)

MRK

Merck

$63.89

0.89 (1.41%)

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

  • 10

    Aug

DVAX Dynavax
$5.60

0.05 (0.90%)

09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
11/14/16
COWN
11/14/16
NO CHANGE
Target $45
COWN
Outperform
Dynavax's Heplisav may still have a path forward, says Cowen
Cowen analyst Phil Nadeau called the CRL issued to Dynavax regarding its Biologics License Application for Heplisav-B "disappointing and concerning," but also noted that the FDA did not request new trials. While the CRL will push approval until late 2017, in a best case scenario, there may still be a path forward for approval of the drug, said Nadeau, who added that he thinks the stock now looks undervalued. The analyst has an Outperform rating and $45 price target on Dynavax shares.
11/15/16
WBLR
11/15/16
NO CHANGE
Target $17
WBLR
Outperform
William Blair still sees 'good chance' for approval of Dynavax's Heplisav
William Blair analyst Y. Katherine Xu lowered her price target for Dynavax Technologies to $17 from $45 after the company received a second Complete Response Letter from the FDA for the Heplisav Biologics License Application. There is still a "good chance" for Heplisav to garner eventual approval, Xu tells investors in a research note. The lack of apparent concerns regarding rare serious autoimmune events is a plus, the analyst contends. Xu keeps an Outperform rating on Dynavax. She points out the company's immuno-oncology program SD-101 is reading out substantial data starting in 2017. Dynavax closed yesterday down 65% to $4.10.
MRK Merck
$63.89

0.89 (1.41%)

04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

ROKU

Roku

$21.87

-0.16 (-0.73%)

07:25
10/23/17
10/23
07:25
10/23/17
07:25
Initiation
Roku initiated  »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

, CLVS

Clovis

$77.50

0.73 (0.95%)

07:24
10/23/17
10/23
07:24
10/23/17
07:24
Initiation
Tesaro, Clovis initiated  »

Tesaro initiated with an…

TSRO

Tesaro

$116.40

0.89 (0.77%)

CLVS

Clovis

$77.50

0.73 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

NCNA

NuCana

$14.08

-0.3 (-2.09%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Initiation
NuCana initiated  »

NuCana initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:23
10/23/17
10/23
07:23
10/23/17
07:23
General news
Futures higher ahead of buy week of earnings »

Stock futures are…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Aimmune, DBV Technologies analyst commentary  »

Aimmune price target…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FL

Foot Locker

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.18

1.73 (1.85%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JPM

JPMorgan

$99.51

1.4 (1.43%)

07:22
10/23/17
10/23
07:22
10/23/17
07:22
Periodicals
JPMorgan, Mosaic Smart Data partner to boost fixed-income trading, Reuters says »

JPMorgan has teamed up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CLVS

Clovis

$77.50

0.73 (0.95%)

07:21
10/23/17
10/23
07:21
10/23/17
07:21
Initiation
Clovis initiated  »

Clovis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BIIB

Biogen

$338.10

-4.32 (-1.26%)

, ESALY

Eisai

$53.38

-0.25 (-0.47%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Hot Stocks
Biogen, Eisai expand existing collaboration agreement »

Eisai Co., Ltd. (ESALY)…

BIIB

Biogen

$338.10

-4.32 (-1.26%)

ESALY

Eisai

$53.38

-0.25 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

NITE

Nightstar Therapeutics

$19.00

-0.1 (-0.52%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Initiation
Nightstar Therapeutics initiated  »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Earnings
Potlatch reports Q3 EPS ex-items 94c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Hot Stocks
Potlatch raises dividend to 40c per share from 37.5c per share »

Potlatch announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAIC

SAIC

$70.88

1.04 (1.49%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Upgrade
SAIC rating change  »

SAIC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GGB

Gerdau

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Gerdau initiated  »

Gerdau resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Vale initiated  »

Vale resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$43.13

-0.16 (-0.37%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Southern Copper initiated  »

Southern Copper resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBR

Fibria Celulose

$16.24

0.45 (2.85%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Fibria Celulose initiated  »

Fibria Celulose resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Hot Stocks
Mike Covey to continue to serve as chairman and CEO of combined Potlatch, Deltic »

The leadership team will…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

GOOG

Alphabet

$988.20

3.75 (0.38%)

, GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Periodicals
Google plans to share revenues with news publishers, FT reports »

Google is planning to…

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

BIIB

Biogen

$338.10

-4.32 (-1.26%)

07:16
10/23/17
10/23
07:16
10/23/17
07:16
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Potlatch, Deltic Timber to combine in all-stock transaction »

Potlatch Corporation…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

PSTI

Pluristem

$1.77

-0.035 (-1.94%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Pluristem receives European patent covering PLX-R18 »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
10/23/17
10/23
07:15
10/23/17
07:15
General news
FX Update: The dollar traded firmer »

FX Update: The dollar…

HAL

Halliburton

$43.33

-0.09 (-0.21%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
Halliburton CEO says 'North American business is hitting on all cylinders' »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.